Kinnate Biopharma Inc. has added two new internally developed next-generation development candidates to its targeted oncology pipeline, a brain-penetrant mitogen-activated protein kinase kinase (MEK) inhibitor and a highly selective hepatocyte growth factor receptor gene (c-Met) inhibitor.
Tumor-associated calcium signal transducer 2 (TROP2) is a promising therapeutic target due to its high expression observed in several solid tumors. Investigators from Jiangsu Hengrui Pharmaceuticals Co. Ltd. have reported preclinical data on the anti-TROP2 antibody-drug conjugate (ADC) SHR-A1921 for the potential treatment of non-small-cell lung cancer (NSCLC).
Junshi Biosciences Co. Ltd.’s PARP inhibitor, senaparib (JS-109/IMP4297), met the primary endpoint of progression-free survival in a phase III ovarian cancer study, according to a prespecified interim analysis.
Immutep Ltd.’s lead immunotherapy candidate, eftilagimod (IMP-321, efti), plus pembrolizumab reverted previous resistance to PD-1/PD-L1 therapy in part B of the TACTI-002 phase II trial in second-line metastatic non-small-cell lung cancer (NSCLC) in patients refractory to anti-PD-1/PD-L1 therapy.
Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR tyrosine kinase inhibitor (TKI) designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation (double mutant) in non-small-cell lung cancer (NSCLC).
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
Hillstream Biopharma Inc. has announced initial results evaluating the synergy of ferroptosis inducer HSB-1216 (quatramer salinomycin) with anti-PD-1 antibody pembrolizumab in the Calu-1 KRAS G12C-mutated non-small-cell lung cancer (NSCLC) cell line.
